Review for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

Mapping Intimacies ◽

10.1111/dom.14078/v2/review3 ◽

2020 ◽

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Review for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

10.1111/dom.14078/v1/review3 ◽

2020 ◽

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Review for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

10.1111/dom.14078/v2/review1 ◽

2020 ◽

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Review for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

10.1111/dom.14078/v2/review2 ◽

2020 ◽

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Author response for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

10.1111/dom.14078/v2/response1 ◽

2020 ◽

Author(s):

Nicklas J. Johansen ◽

Thomas F. Dejgaard ◽

Asger Lund ◽

Camilla Schlüntz ◽

Emil L. Larsen ◽

...

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Author Response ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Review for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

10.1111/dom.14078/v1/review1 ◽

2020 ◽

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Decision letter for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

10.1111/dom.14078/v1/decision1 ◽

2020 ◽

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14078 ◽

2020 ◽

Vol 22 (9) ◽

pp. 1639-1647

Author(s):

Nicklas J. Johansen ◽

Thomas F. Dejgaard ◽

Asger Lund ◽

Camilla Schlüntz ◽

Emil L. Larsen ◽

...

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Decision letter for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

10.1111/dom.14078/v2/decision1 ◽

2020 ◽

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Review for "Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial"

10.1111/dom.14078/v1/review2 ◽

2020 ◽

Keyword(s):

Cardiovascular Disease ◽

Type 1 Diabetes ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(20)30030-9 ◽

2020 ◽

Vol 8 (4) ◽

pp. 313-324 ◽

Author(s):

Nicklas J Johansen ◽

Thomas F Dejgaard ◽

Asger Lund ◽

Camilla Schlüntz ◽

Christian S Frandsen ◽

...

Keyword(s):

Type 1 Diabetes ◽

Glycaemic Control ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Short Acting ◽

Download Full-text